Tianzhen Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tianzhen Hu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Baoqiang Wang
Department of Radiation Oncology, Lishui City People’s Hospital, Lishui 323000, China
1 shared publication Chengyun Pan
Department of Haematology, Affiliated Hospital of Guizhou Medical University, Guizhou, China
1 shared publication- Hanying Wang
Department of Radiation Oncology, Lishui City People’s Hospital, Lishui 323000, China
1 shared publication - Hong Ye
Department of Radiation Oncology, Lishui City People’s Hospital, Lishui 323000, China
1 shared publication - Jishi Wang
Laboratory of Hematopoietic Stem Cell Transplantation Centre of Guizhou Province, Guiyang, Guizhou, China; Department of Haematology, Affiliated Hospital of Guizhou Medical University, Guizhou, China
1 shared publication - Lele Ma
Department of Emergency Medicine, People’s Hospital of Jingning She Autonomous County, Jingning 323500, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2024 (1)
The Neoadjuvant Administration of PD‐1 Inhibitor plus Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous‐Cell Carcinoma
Objective. Programmed cell death‐1 (PD‐1) inhibitors have shown potency for neoadjuvant therapy in several cancers, while their administration combined with concurrent chemoradiotherapy (CCRT) as a neoadjuvant therapy for locally advanced esophageal squamous‐cell carcinoma (ESCC) is seldom reported. The current study aimed to investigate the pathological response, survival, and safety of neoadjuvant PD‐1 inhibitor plus CCRT in locally advanced ESCC patients. Methods. Twenty‐five locally advanced ESCC patients who underwent PD‐1 inhibitor plus CCRT neoadjuvant therapy were retrospectively reviewed. Data regarding radiological response, pathological response, disease‐free survival (DFS), overall survival (OS), and adverse events were retrieved. Results. Two (8.0%), 14 (56.0%), 9 (36.0%), and 0 (0.0%) patients had a clinical response of complete response, partial response, stable disease, and progressive disease after neoadjuvant therapy by radiological evaluations, respectively. Notably, 25 (100.0%) patients had successful tumor resections, 24 (96.0%) patients realized R0 resection, and 13 (52.0%) patients achieved pathological complete response (pCR) by pathological evaluations. Regarding survival profiles, the 1‐year and 2‐year accumulating DFS rates were 90.0% and 74.6%, respectively; then, the 1‐year and 2‐year accumulating OS rates were 95.5% and 90.4%, respectively. The top prevalent adverse events were fatigue (48.0%), nausea and vomiting (40.0%), leukopenia (36.0%), neutropenia (36.0%), and peripheral neuropathy (36.0%). In addition, grades 3‐4 adverse events included peripheral neuropathy (12.0%), nausea and vomiting (4.0%), leukopenia (4.0%), neutropenia (4.0%), anemia (4.0%), and pruritus (4.0%). Conclusion. Neoadjuvant PD‐1 inhibitor plus CCRT shows a good efficacy and acceptable tolerance for locally advanced ESCC treatment, but further large‐scale study validation is needed.
- 1 January 2024
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2024 (1)
Open AccessThe Neoadjuvant Administration of PD‐1 Inhibitor plus Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous‐Cell Carcinoma
Objective. Programmed cell death‐1 (PD‐1) inhibitors have shown potency for neoadjuvant therapy in several cancers, while their administration combined with concurrent chemoradiotherapy (CCRT) as a neoadjuvant therapy for locally advanced esophageal squamous‐cell carcinoma (ESCC) is seldom reported. The current study aimed to investigate the pathological response, survival, and safety of neoadjuvant PD‐1 inhibitor plus CCRT in locally advanced ESCC patients. Methods. Twenty‐five locally advanced ESCC patients who underwent PD‐1 inhibitor plus CCRT neoadjuvant therapy were retrospectively reviewed. Data regarding radiological response, pathological response, disease‐free survival (DFS), overall survival (OS), and adverse events were retrieved. Results. Two (8.0%), 14 (56.0%), 9 (36.0%), and 0 (0.0%) patients had a clinical response of complete response, partial response, stable disease, and progressive disease after neoadjuvant therapy by radiological evaluations, respectively. Notably, 25 (100.0%) patients had successful tumor resections, 24 (96.0%) patients realized R0 resection, and 13 (52.0%) patients achieved pathological complete response (pCR) by pathological evaluations. Regarding survival profiles, the 1‐year and 2‐year accumulating DFS rates were 90.0% and 74.6%, respectively; then, the 1‐year and 2‐year accumulating OS rates were 95.5% and 90.4%, respectively. The top prevalent adverse events were fatigue (48.0%), nausea and vomiting (40.0%), leukopenia (36.0%), neutropenia (36.0%), and peripheral neuropathy (36.0%). In addition, grades 3‐4 adverse events included peripheral neuropathy (12.0%), nausea and vomiting (4.0%), leukopenia (4.0%), neutropenia (4.0%), anemia (4.0%), and pruritus (4.0%). Conclusion. Neoadjuvant PD‐1 inhibitor plus CCRT shows a good efficacy and acceptable tolerance for locally advanced ESCC treatment, but further large‐scale study validation is needed.